Low-dose aspirin in Essential Thrombocythemia
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-12 — CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA): CRETA framing reinforces the accelerated platelet turnover rationale already underpinning twice-daily low-dose aspirin in ET, and positions clopidogrel (with possible dose escalation) as the alternative for aspirin-intolerant patients. (novelty: 3)
Open questions
Related
Contributing findings
CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA)
12-jun-2026
novelty 3
per-area 2
strengthens